CJC-1295/Ipamorelin: Clinical Guide for Prescribing Practices
CJC-1295/Ipamorelin is one of the most popular peptide combinations in clinical practice. CJC-1295 is a growth hormone releasing hormone (GHRH) analog, while Ipamorelin is a selective growth hormone secretagogue. Together they stimulate natural growth hormone production without significantly affecting cortisol or prolactin levels.
Also Known As
How CJC-1295/Ipamorelin Works
CJC-1295 is a synthetic GHRH analog (modified GRF 1-29) that binds the GHRH receptor on anterior pituitary somatotrophs, stimulating GH gene transcription and secretion [1]. Ipamorelin is a pentapeptide ghrelin mimetic that activates the GHS-R1a receptor, amplifying GH pulse frequency without displacing cortisol or prolactin signaling [2]. The combination produces synergistic GH release by simultaneously increasing pulse amplitude (GHRH pathway) and pulse frequency (ghrelin pathway), closely mimicking endogenous GH regulation [3].
Clinical Evidence
Clinical studies demonstrate that GHRH analogs combined with GH secretagogues produce 2 to 3 fold greater GH release than either agent alone [3]. Ipamorelin has been shown in phase II trials to selectively elevate GH without significant effects on ACTH, cortisol, or prolactin [2]. CJC-1295 with DAC demonstrated sustained IGF-1 elevation for 6 to 14 days following a single injection in healthy adults [1]. The combination is the most widely prescribed GH peptide protocol in US longevity medicine.
Clinical Uses
Patient Selection and Screening
Ideal candidates include adults over 30 with documented low or declining IGF-1 levels, poor body composition despite adequate exercise, impaired recovery, or age-related sleep quality decline [4]. Screen with baseline IGF-1, comprehensive metabolic panel, fasting glucose, and HbA1c. Contraindications include active malignancy, untreated pituitary pathology, uncontrolled diabetes, and pregnancy. Use caution in patients with history of carpal tunnel syndrome or edema-prone conditions.
Dosing and Administration
CJC-1295 (no DAC)/Ipamorelin is typically dosed at 100 to 300mcg of each component via subcutaneous injection, administered 1 to 3 times daily [1][2]. Most protocols use a single bedtime injection (200mcg/200mcg or 300mcg/300mcg) to align with natural nocturnal GH pulsatility. Titrate upward from lowest effective dose over 2 to 4 weeks. Common cycles run 12 to 16 weeks followed by 4 to 8 weeks off, though some clinicians prescribe continuously with periodic IGF-1 monitoring. Dosing should be individualized based on IGF-1 response and clinical outcomes. All dosing decisions require physician clinical judgment.
Route: Subcutaneous injection
Protocol notes: Typically administered via subcutaneous injection, often before bedtime to align with natural GH pulsatility.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
CJC-1295/Ipamorelin is the highest-volume GH peptide in most practices and serves as an anchor product for longevity programs [3]. Wholesale cost from compounding pharmacies typically ranges from $40 to $80 per vial (sufficient for 4 to 6 weeks), while practices commonly charge patients $250 to $500 per month inclusive of medication and clinical oversight. High patient retention rates (often 6 to 12 months or longer) make this a strong recurring revenue line. Many practices bundle with quarterly labs and follow-up consultations.
FDA Category Status
Expected to return to Category 1 per February 2026 HHS announcement
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe CJC-1295/Ipamorelin through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
Can CJC-1295/Ipamorelin be prescribed via telehealth?
How do practices typically price CJC-1295/Ipamorelin programs?
References
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561
- Ionescu M, Bhargava R. GHRH and GH secretagogues: clinical significance. Growth Horm IGF Res. 2003;13 Suppl A:S28-32
- Nass R et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes. Ann Intern Med. 2008;149(9):601-611
Related Peptides in Growth Hormone Support
AOD-9604
Growth Hormone Support
View Guide →
Tesamorelin
Growth Hormone Support
View Guide →
Sermorelin
Growth Hormone Support
View Guide →
Ipamorelin
Growth Hormone Support
View Guide →
MK-677
Growth Hormone Support
View Guide →
GHRP-2
Growth Hormone Support
View Guide →
GHRP-6
Growth Hormone Support
View Guide →
Hexarelin
Growth Hormone Support
View Guide →
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe CJC-1295/Ipamorelin Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe CJC-1295/Ipamorelin Through Karpa